About Contact Us Careers
Sign In

Mucopolysaccharidosis Treatment Market - Top Companies and Manufacturers

  • Report ID: 5215
  • Published Date: Aug 02, 2024
  • Report Format: PDF, PPT

Companies Dominating the Mucopolysaccharidosis Treatment Market

    • Shire Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Sanofi Genzyme
    • BioMarin Pharmaceutical
    • Ultragenyx Pharmaceutical
    • Regenxbio
    • Abeona Therapeutics
    • Sangamo Therapeutics
    • Denali Therapeutics
    • Lysogene
    • ArmaGen
Browse Key Market Insights with Data Illustration:

In the News

  • Beyfortus™ is a novel, long-acting RSV pre-exposure prophylaxis (pre-EP) monoclonal antibody developed by Sanofi and Genzyme. The vaccine was found to be safe and effective in preventing RSV infection in infants from 6 weeks to 5 months of age. The CDC's Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend routine use of Beyfortus™ for all infants in the United States.
  • Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment. Qunol® is a leading brand of nicotinamide riboside (NR) supplements, which are naturally produced in the body and play a role in cellular energy production.

Author Credits:  Radhika Pawar


  • Report ID: 5215
  • Published Date: Aug 02, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of mucopolysaccharidosis treatment is evaluated at USD 11.56 Billion.

The mucopolysaccharidosis treatment market size was over USD 10.79 Billion in 2023 and is likely to exceed USD 28.99 Billion by the end of 2036, growing at over 7.9% CAGR during the forecast period i.e., between 2024-2036. Increasing demand for healthcare sector is the major factor driving the market growth.

Asia Pacific industry is projected to account for largest revenue share of 38% by 2036, backed by rising awareness campaigns and improved medical education have led to higher rates of MPS diagnoses in the region.

Shire Inc., Sanofi Genzyme, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Regenxbio, Abeona Therapeutics, Sangamo Therapeutics, Denali Therapeutics, Lysogene, ArmaGen
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample